Savara Inc.

NASDAQ•SVRA

CEO: Mr. Matthew Pauls J.D., M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2017-04-28

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.

Contact Information

1717 Langhorne Newtown Road, Suite 300, Langhorne, PA, 19047, United States

512-614-1848

www.savarapharma.com

Market Cap

$1.18B

P/E (TTM)

-10.8

18.2

Dividend Yield

52W High

$7.01

52W Low

$1.89

52W Range

76%

Rank58Top 85.6%

2.3

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.13+0.00%

4-Quarter Trend

FCF

-$25.06M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

MOLBREEVI BLA Filed BLA for MOLBREEVI resubmitted Dec 2025; FDA formally filed Feb 2026 with Priority Review designation.

IMPALA-2 Trial Positive Results Primary endpoint DLCO showed 6.0 percentage points improvement over placebo (p=0.0007), indicating durability of effect.

Financing Secured Post-Trial October 2025 offering raised $140.2 M net proceeds; debt facility provides potential $75 M more upon approval.

Cash Position Strong Cash and investments totaled $235.7 M as of December 31, 2025, supporting ongoing clinical development activities.

Risk Factors

Dependence on Single Candidate Business success substantially dependent on MOLBREEVI clinical development, regulatory approval, and commercial success.

Continued Operating Losses Incurred $118.8 M net loss in 2025; expect substantial losses requiring future capital raises for operations.

G&A Expense Surge General and administrative expenses rose 68.0% to $42.1 M in 2025 driven by strategic workforce expansion efforts.

Regulatory Approval Uncertainty Regulatory authorities retain discretion to delay or deny approval, potentially preventing timely marketing of MOLBREEVI.

Outlook

Advance Regulatory Approval Continue pursuing MOLBREEVI regulatory approval in U.S., EU, and UK following BLA filing in February 2026.

Establish Dual Supply Chain Plan to qualify a second source drug product manufacturer following approval to establish a dual-source supply chain.

Prepare Commercial Launch Will need to increase organization size and establish sales and marketing infrastructure upon receiving regulatory approval.

Pediatric Trial Progress Pediatric IMPACT trial for autoimmune PAP is currently ongoing following acceptance by EMA and MHRA.

Peer Comparison

Revenue (TTM)

GERN

$183.88M

+138.8%

RGNX

$170.44M

+104.5%

MGTX

$81.39M

+144.6%

Gross Margin (Latest Quarter)

NBTX

100.0%

+0.0pp

ATXS

100.0%

+0.0pp

MGTX

99.4%

+33.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
TNGX	$3.09B	-30.5	-50.3%	8.4%
TYRA	$1.91B	-17.7	-41.2%	2.1%
NBTX	$1.63B	-56.8	31.2%	140.7%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 11, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data